Employment of the Triple Helix concept for development of regenerative medicine applications based on human pluripotent stem cells by Peter Sartipy & Petter Björquist
Sartipy and Björquist Clinical and Translational Medicine 2014, 3:9
http://www.clintransmed.com/content/3/1/9REVIEW Open AccessEmployment of the Triple Helix concept for
development of regenerative medicine
applications based on human pluripotent stem
cells
Peter Sartipy1,2* and Petter Björquist1,3Abstract
Using human pluripotent stem cells as a source to generate differentiated progenies for regenerative medicine
applications has attracted substantial interest during recent years. Having the capability to produce large quantities
of human cells that can replace damaged tissue due to disease or injury opens novel avenues for relieving
symptoms and also potentially offers cures for many severe human diseases. Although tremendous advancements
have been made, there is still much research and development left before human pluripotent stem cell derived
products can be made available for cell therapy applications. In order to speed up the development processes, we
argue strongly in favor of cross-disciplinary collaborative efforts which have many advantages, especially in a
relatively new field such as regenerative medicine based on human pluripotent stem cells. In this review, we aim to
illustrate how some of the hurdles for bringing human pluripotent stem cell derivatives from bench-to-bed can be
effectively addressed through the establishment of collaborative programs involving academic institutions, biotech
industries, and pharmaceutical companies. By taking advantage of the strengths from each organization, innovation
and productivity can be maximized from a resource perspective and thus, the chances of successfully bringing
novel regenerative medicine treatment options to patients increase.
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Human pluripotent stem cells (hPSC) can be isolated
from in vitro fertilized eggs or they can be generated
from somatic cells through the process referred to as
re-programming [1,2]. Established hPSC lines can be
propagated indefinitely and the cells can differentiate
into virtually any specialized cell type of the adult. The
ability to harness these unique properties of hPSC
forms the foundation for the tremendous expectations
on the applications of these cells, and their derivatives,
for treating human diseases which are characterized by
tissue degeneration and cell loss. Over the last decade
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reproduction in any medium, provided the origundifferentiated hPSC has improved substantially. In
parallel, the understanding of hPSC differentiation on
a molecular- and mechanistic level has increased dramatic-
ally, resulting in the establishment of efficient differenti-
ation protocols for several human cell types [3]. When
combining this know-how, it is easy to appreciate that the
expectations on hPSC in the area of regenerative medicine
are high, since the possibility to create large amounts of hu-
man cell types seems to be just around the corner. These
expectations are in many ways valid; however, there are still
substantial hurdles that need to be overcome before regen-
erative medicine applications based on hPSC could reach
the market.
Human pluripotent stem cells have started to find
their way into the clinical setting and we have wit-
nessed rapid progress in this field during recent years.
The first FDA-approved clinical trial initiated by Geron
(http://www.geron.com) in 2009 using their cell therapy. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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oligodendrocyte progenitor cells derived from human
embryonic stem cells (hESC), targeted spinal cord in-
jury. Although this study was halted for financial reasons
in 2011, the patients that already had received the cellular
transplants will be monitored for a period of 15 years
according to the original study protocol using public
state funding. Two other studies initiated by Advanced
Cell Technology (http://www.advancedcell.com) have
received FDA-approval for transplantation of their cell
therapy product, MA09-hRPE, to patients with Advanced
Dry Age Related Macular Degeneration or Stargardt's
Macular Dystrophy. MA09-hRPE is a population of
hESC-derived retinal pigment epithelium cells and the
hope is to be able to slow or halt the process of blindness
associated with these degenerative diseases. Initial safety
data have been published and appear promising [4]. In
parallel, the Japanese authorities have given their ap-
proval to the first clinical study using human induced
pluripotent stem cell (hiPSC)-derived cells. This inves-
tigation, led by researchers at the RIKEN Center for
Developmental Biology (http://www.riken.jp), Kobe,
Japan, is targeting patients suffering from exudative
(wet-type) Advanced Macular Degeneration. The study
will take advantage of a clinically compliant protocol
involving the establishment of autologous hiPSCs from
each of the study subjects and a differentiation method
to generate retinal pigment epithelium cells for subse-
quent transplantation back to the patients. Although
these recent developments are exciting and could rep-
resent the beginning of a new era in regenerative medi-
cine, concerns have been raised, and it has been argued
that some safety issues require additional investigations in
order to better assess the risks involved when transplanting
hPSC-derived cells to humans [5]. Indeed, for the whole
field of hPSC-based cell therapy it is a lot at stake, and
failure of the initial clinical trials due to safety reasons will
have substantial negative impact on any future develop-
ments in this space. One can expect that these pioneering
clinical studies will be monitored closely by the regulatory
agencies, scientists, investors/financers, as well as patient
groups and the general public.
For everyone involved in stem cell based regenerative
medicine projects it is clear that bringing new hPSC-
based therapies from bench-to-bed is an extremely com-
plex and costly process. Challenges ranges from scientific/
technical- to clinical- and regulatory- as well as financial/
business development related hurdles. One way to address
complex challenges is to establish cross-disciplinary
collaborations and set up teams which are equipped to
address each of these challenges in an efficient way.
This requires access to specialist competencies from
individuals belonging to academic research centers, small
and medium size biotech, as well as large pharma andregulatory agencies. The Triple Helix concept typically
refers to the hybridization between university, industry,
and government to generate knowledge and innovation
[6]. In our model described here (Figure 1), we include
university, small- and medium size enterprises (SME)
(i.e., biotech industry), and large pharmaceutical companies
in the Triple Helix, and we will illustrate how benefits
and strengths can be captured from each organization
in order to drive the development of therapeutic appli-
cations of hPSC.
Review
Setting up cross-disciplinary collaborations for regenerative
medicine programs
Forming cross-disciplinary collaborations may at a first
glance appear challenging. However, by appropriately
matching complementary skills and interests, the process
can be straight forward. Although each partner may have
separate short term goals, the foundation in the program
must be focused on the final long term goal which is to
cure patients and improving quality-of-life for individuals
who are suffering from, as-of-yet, untreatable degenerative
diseases. The main advantage of bringing together expert-
ise from academic institutes, SME, and large pharma into
one collaborative program is that one can capture the
benefits and strengths from each organization in a timely
fashion. In the following section, we aim to illustrate
this by exemplifying some of the challenges of bringing
hPSC-based therapies from bench to bed and propose
how these issues can be addressed through creative
interdisciplinary collaborations.
The criteria for identifying key partners in industry
and academia should be comprised of several important
aspects. The project team should include access to sci-
entific and technical expertise in a number of areas in-
cluding developmental biology, stem cell differentiation,
cell production, and process development including
quality assurance and quality control. From the medical
side it is important to bring in experts and key-opinion-
leaders in the disease area that is being targeted in order
to have in-depth understanding of the disease mechanisms
and pathology, and also knowledge of the currently avail-
able treatments, if there are any. Other important compe-
tencies to include are from clinical development and the
regulatory side. Based on the recent advent of this field,
the experience from hPSC-based therapeutic applications
is today limited both from the clinical- as well as from the
regulatory aspects. This makes it important to follow the
developments closely and having the opportunity to adapt
quickly to any alterations in the clinical and regulatory
landscape that may arise. It is expected that adjustments
of the program need to be done as the developments pro-
gress. Thus, it is critical that the project team is highly
flexible and can adapt to new conditions, both based on
Figure 1 The Triple Helix concept. Cartoon illustrating the Triple Helix model depicting how academia, biotech industry (SME), and
pharmaceutical industry may work close together in order to synergize development of novel regenerative medicine applications for the
improvement of human health.
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in the external environment and regulatory landscape. For
example, it was recently highlighted that most of the hESC
lines listed on the NIH Stem Cell Registry do not comply
with US Food and Drug Administration’s requirements for
commercializable starting material for medicinal products
[7]. Notably, this is due to the restricted use of NIH funds
for the derivation and use of hESC lines which is not
compatible with the FDA regulations for biologically
generated therapeutic products for human use. In Europe,
the situation is similar, and funds from the European
Commission cannot be used for the derivation of new
hESC lines, which will be needed in order to bring
hESC-based therapies to the market. Thus, research
programs relying on such federal- and international
grants are currently facing substantial regulatory hurdles
and these issues must be resolved. Investments in product
development and commercialization using non-FDA
approved hESC-lines seem unlikely from the industry
side since these efforts may need to be repeated using a
starting material that fulfils the FDA regulations.
One advantage of adopting the modified Triple Helix
concept consisting of the academic institute, SME, and
the pharmaceutical industry is that the risk of internal
competition between the organizations in the project team
can be minimized. In a simplistic view, one could consider
the role of the academic researchers to be focused
mainly on the basic science aspects of the project, such
as furthering the fundamental understanding of the mo-
lecular processes involved in cell differentiation to specific
lineages and deciphering the mechanisms critical for cell
survival and functional integration post-transplantation. Itshould be noted that many academic institutions have
become increasingly interested in supporting intellec-
tual property protection by their researchers. This may
appear as an obstacle for industrial implementation
since it may involve negotiating terms and conditions
for technology licensing also with the academic institute.
However, investments from the industry is preferable done
in areas with freedom to operate and patent protection,
thus having a unique and protected technology would
rather increase the interest from industry partners. While
the academic partners would focus on the basic science,
the SME, on the other hand, would undertake the indus-
trial implementation and transfer the knowledge gener-
ated at the academic institute and perform tasks such as
standardization of processes and quality control. Another
typical role for the SME partner would be to head the
refinement of enabling assets such as culturing media,
up-scaling technologies for undifferentiated and differenti-
ated cells, as well as derivation of new hPSC lines of GMP
grade. Finally, animal experimentation, pre-clinical toxicity
testing, and clinical development entails large resources
and an organization to meet regulatory requirements, and
is today probably best led by large pharma. It may appear
that the different partners have discrete roles, which could
certainly be the case in some situations, but the key aspect
here is still close collaboration. In order for the project to
move forward efficiently it is imperative that all partners
have detailed insights into each other’s activities. Regular
joint project meetings are a simple tool to stimulate dis-
cussions and interactions between the project teams and
increase transparency between the partners. In addition,
fostering and supporting an environment that encourages
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researchers, clearly have positive effects for generating
a creative and constructive atmosphere which is a crucial
factor for a successful project progression. Especially in
the process of transferring knowledge and technologies
from one organization to another, part of the success
depends on the opportunity of having key individuals
physically following the implementation phase on a
practical level. Indeed, tech transfer is often problematic
in life science and biotech due to the delicate procedures
involved when handling biological material. In particular,
culturing and differentiating hPSCs are complex processes
and transferring methodologies across laboratories are
challenging [8]. However, by taking advantage of the
cross-disciplinary approach described here we believe
that the strength of the Triple Helix model is highly
beneficial for the development of clinical applications
based on hPSC.
Addressing hPSC-challenges with cross-disciplinary teams
Although major advancements have been achieved over
the last decade related to the culture and directed dif-
ferentiation of hPSC, we are still at the early stages of
understanding on a detailed level how these processes
are governed. For instance, our knowledge about the
phenomenon of pluripotency remains limited. The clues
we have at hand, thus far, involve an insight into the
transcriptional machinery that regulate and to some
extent control the pluripotent state [9]. Transcription
factors, such as Oct4, Sox2, Nanog, Klf-4, and c-Myc,
have all been observed to be critical for maintaining the
pluripotent state of hESC, and also been shown to be
instrumental for the reprogramming of somatic cells
into iPSC [2]. A much more thorough understanding
of the pluripotent state will be important to improve
and better define culturing systems for large scale pro-
duction of homogenous undifferentiated hPSC and to
make these cells ready for directed differentiation into
specialized cells. It should be noted that for the indica-
tions currently targeted in the ongoing and planned
clinical trials using hPSC-derived retinal pigment epi-
thelium cells, the number of cells that are transplanted
to the patients are relatively low (about 50,000 cells)
[4], but the cell dosage expected for other indications
such as diabetes and heart disease are in the 10 billion
range [10]. Taking these cell numbers into the calculation,
it is clear that currently used culturing systems will be far
from sufficient and bioreactors or other types of large
volume suspension culturing systems must be developed
to meet the needs from patients. Such developments
require the collaborative effort between basic stem cell
biologist, engineers, and experts in bioprocessing and
would fit well into the Triple Helix model. For example,
an SME developing culture vessels or bioreactors wouldinstantly get access to specialized knowledge in stem cell
biology through collaborations with academic teams
and on the other side they would have a bench-marking
partner in the large pharma which could provide critical
feed-back on new developments as they progress. Notably,
many times the pharmaceutical industry is entering regen-
erative medicine from being experts in a certain disease
area but without detailed knowledge about hPSC tech-
nologies per se. Here, the SMEs and academic teams may
play an important role as experts in the field bringing key
aspects of this new technology into the larger company’s
organization and procedures. An example of successful
transfer of technologies from academy to industry is
the clinical applications of hESC-derived oligodendro-
cyte progenitors which originated from University of
California at Irvine and later led to the use of these cells for
implantation in human spinal cord injuries in the clinical
study by Geron mentioned above [11].
The derivation and culture of clinically compliant
hPSC has been described [12] but limitations in scale
of production and high costs remain significant chal-
lenges. In addition to the technical issues involved, for
ethical reasons, it is important to establish the donor
consent documentation appropriately and utilize forms
that specifically states that the cells will be used for cell
therapy purposes. We have witnessed many examples
of hPSC lines which have been derived using donor
consent forms that only cover “in vitro research use” of
the cells and consequently prevent the lines to be used
in a clinical and commercial setting. Thus, we believe that
it will be required in the future to derive new hPSC lines, of
clinical grade, using appropriate donor consent. Although
the hESC-lines used in the clinical trials described above
have received post-derivation approval for clinical use,
we believe that for broader use, future hPSC lines should
be derived under strict GMP conditions from the start.
That is, these cell lines should be derived strictly both
feeder- and xeno-free in order to be compatible with future
requirements from the regulatory agencies world-wide.
Such cell lines are still not available, but this work is in
progress in our own laboratories as well as in others.
Critical bottlenecks to be addressed include the develop-
ment of standardized feeder- and xeno free conditions for
establishment of hPSC lines encompassing identification
of qualified reagents, which is a non-trivial task. Neverthe-
less, recent reports have shown that the establishment of
iPSC lines can be done without genetic manipulation and
this process may greatly simplify regulatory compliance in
the future [13]. Furthermore, differentiation protocols that
may fulfill the criteria set for GMP production have also
been described for various cell types including retinal pig-
ment epithelium cells [4], vascular cells [14], and neurons
[15]. However, substantial additional basic research is
needed to develop a cell therapy product based on hPSC,
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and industry is important. Taking advantage of the deep
knowledge in developmental biology and stem cell dif-
ferentiation available at the Universities and combining
this with early input from industry will pave the way for
efficient establishment of industry-ready protocols for
cell production. Today, directed hPSC differentiation is
typically achieved by sequentially exposing the cells in a
delicate time- and dose dependent manner to growth
factors and signaling molecules that enriches the final
cultures for a specific cell type, which may or may not
require further purification. In most cases, the meth-
odologies developed at the research bench necessitate
substantial modifications to reach the criteria needed
for industrial implementation. For example, for GMP
production, it is a formal requirement to have traceable
and qualified reagents as well as defined culture medium.
In addition, the cost-of-goods is an important aspect which
is often overlooked at the early stages of protocol develop-
ment in small scale. Before going into large scale process
development it is highly advantageous to have defined
differentiation protocols in which expensive protein growth
factors have been replaced by less expensive alternatives
(e.g., small molecules). There are several examples in
which this has been successfully accomplished both for
establishment of hPSC lines and for directed differentiation
efforts [16]. A thorough understanding of the basic mecha-
nisms involved in cell type specific differentiation is needed
to efficiently make this transition to reduce the cost-of-
goods. From a practical perspective, handling and differ-
entiating hPSC have traditionally encompassed substantial
manual labor and this is not compatible with large scale
production where automation is a key factor. Simplifying
the practical moments and reducing the physical manipu-
lations of the cell cultures are also issues that are import-
ant to deal with at an early stage of protocol development
and cross-disciplinary collaborations are well equipped to
address these challenges.
Besides the challenges in setting up a production
platform that can deliver an hPSC-based therapeutic
product at an acceptable cost and scale, it is important
to define the optimal type of hPSC-derivative to finally
transplant. Grafting undifferentiated hPSC is associated
with a substantial risk of tumor formation [17] and de-
pending on the disease it may be appropriate to derive
a committed progenitor population or a more fully differen-
tiated mature phenotype. Taking the example of diabetes, it
has been reported in pre-clinical animal models that by
xeno-grafting pancreatic endoderm derived from hESC, it
was possible to cure animals with experimentally induced
diabetes [18]. This strategy is now further explored and
developed towards a clinical application by Viacyte using
their PEC-01™ cells (http://www.viacyte.com). An alterna-
tive approach, currently explored in our ongoing programtogether with Novo Nordisk (http://www.novonordisk.com)
and Lund University (Sweden), is to develop fully functional
glucose-responsive β-cells and in the end to transplant
these cells to patients using an encapsulation technique.
In principal, there are pros and cons with both strategies.
The progenitor strategy encompasses the possibility of in
situ cell expansion, having the benefit of requiring smaller
cell doses and one may speculate that progenitors are able
to survive and functionally integrate post-transplantation
more efficiently than more mature cells. On the other hand,
the fully differentiated cell therapy product may represent
a “safer” product since it is a post-mitotic cell population
(i.e., low risk of tumor formation) which can be more
precisely dosed. Encapsulation of islet cell grafts has
been successfully reported both in animal models and
human subjects [19,20]. In the specific situation of cell
therapy for diabetes, it is not necessary to achieve func-
tional integration with the host tissue since the cells are
aimed to serve as glucose sensor and insulin producers,
and their contact only via with the blood circulation should
be sufficient. For diabetes treatment using cell therapy, the
consensus today is that the cells should be encapsulated in
order be protected from the immune system of the host,
but at the same time allowing nutrients and hormones to
cross the membrane. The exact site of transplantation is
still under consideration but the liver or in the subcutane-
ous space has been proposed to be suitable sites. However,
most experimental cell transplantations are delivered
directly to the site of injury or in an adjacent region by
injecting a small volume of a cell suspension using fine
needles or glass capillaries. Alternatives include a systemic
approach via intravenous infusions. Besides encapsula-
tion, other options to avoid a devastating immune
reaction would be to generate banks of matching cell
lines (so-called “haplobanks”) or to engineer the genome
of cells to cause less response from the host by for example
knocking out immune-reaction causing antigens [21]. The
use of mesenchymal stromal cells as immunomodulatory
agents also represents an alternative to suppress immune
reactions caused by implanted stem cell derivatives [22,23].
In each specific disease indication it is critical to assess
which strategy is most appropriate and many factors need
to be taken into consideration. Thus, the cross-disciplinary
approach clearly has benefits in these situations where
aspects related to defining cell product maturation stage,
administration and delivery strategy need to be evaluated
in the context of engraftment capacity, homing, survival,
activation of the immune system, and functional integra-
tion of the cells at the site of injury.
When getting closer to the clinical situation, issues
related to quality control and testing of the final cell
therapy product are important. It is likely that development
of quality standards and characterization methods for
each hPSC-based therapeutic product and intended clinical
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defining and characterizing the cell therapy product is the
possibility for using mixed populations of cells to achieve
the therapeutic effect. A pure population of only one
cell type, which could be easier to define, may be less
potent and effective. The potency testing is critical for
the development of hPSC-based cell therapy products
and is needed before progression to phase III clinical
trials. However, a strict potency assay, ideally a product’s
in vivo mechanism of action, may not be possible since
the product may encompass complex multiple functions,
some of which are not well defined. Most likely, novel
potency assays needs to be developed and this requires
innovation and basic research in combination with
standardization and industrial quality systems and the
pharma industry has a key role in these processes. Rele-
vant pre-clinical testing in vivo requires well deigned and
suitable animal models. Common for all hPSC-derived cell
therapy products is that one needs to consider effects that
relate to xeno-transplantation when testing the human
cells in animal models. How this parameter will affect
the interpretation of the results must be addressed on a
case-to-case basis and is at this stage difficult to predict.
Nevertheless, establishment of general strategies and guide-
lines on how to assess potency and safety of hPSC-derived
cellular products is critical, and close interactions with the
regulatory agencies are very important in order to safely
translate experimental cell therapy to the clinic. The choice
of trial design and regulatory issues may also cause difficul-
ties and lead to clinical trial failures, further underscoring
the importance of the close interactions with the regulatory
agencies already at an early stage.
Development of hPSC-based cell therapies are expected
to be long and expensive and clinical failure can be due to
other factors besides efficacy and safety. We have already
witnessed termination of clinical programs due to financial
reasons and business strategies (http://www.geron.com).
A collaborative project between academy, SME, and
large pharma can take advantage of different funding
mechanisms and there are opportunities to tap into
various external sources of support. Funding for basic
research carried out in the academic setting is available,
on competitive grounds, from national research councils
and institutes (e.g., National Institutes of Health in the US
and Medical Research Council in the UK). In addition,
many other organizations, active nationally or globally, are
also supporting research towards hPSC-based cell therapy
(e.g., Juvenile Diabetes Research Foundation, http://www.
jdrf.org). In the private sector, SMEs have the possibility
to attract venture capital to fund efforts in regenerative
medicine. In addition and perhaps most importantly, the
pharmaceutical companies have many times the possi-
bility to directly support the project using their internal
resources. Besides individually applying for grants orsecuring other type of funding, the partners in the Triple
Helix model can also join together and obtain consortium
grants or support based on collaborative networks
from international initiatives such as the Framework
Programs funded by the European Union. In the US,
the NIH also has specific funding programs that pro-
mote risky research collaborations between industry
and academia, such as the Small Business Innovation
Research (SBIR) and Small Business Technology Transfer
(STTR) Programs. In addition, the Technology Strategy
Board in the UK recently established Cell Therapy Catapult
(http://www.ct.catapult.org.uk), a not-for-profit organization,
with the aim to help businesses take innovative ideas in
the area of cell therapy through to commercialization.
This is one example of how governmental initiatives can
help taking products into the clinic and de-risking them
for further investment. Taken together, having partners
aligned with the Triple Helix model, which cover both non-
profit and for-profit organizations, is of great advantage
when developing hPSC-based cell therapy applications
since this will allow the flexibility to fund the research
and development using a variety of sources decreasing the
financial risk for the project for the individual partners.
Conclusions
Most fruitful and successful collaborations are characterized
by the “win-win situation” where all partners have clear
benefits of working together and they share a mutual
trust and respect and an openness to share information
and data among participating partners. In the challenging
process of developing novel hPSC-based therapeutic
applications it is imperative to establish collaborations
and engage expertise from various disciplines and organi-
zations. The Triple Helix model appears well suited for
addressing some of the challenges, and the benefits for
each organization can be identified. For example, through
the course of a successful hPSC-based therapy project,
research data will be generated that most likely will be
possible to publish in high-impact journals which will
profile the academic researchers in the field and form
the foundation for future grant applications. The SMEs
can benefit from the program since they can secure im-
portant intellectual property and build their business
and technology platform to become the partner-of-
choice also in other hPSC-based therapeutic programs.
In addition, the SMEs may become the manufacturer of
the final cell therapy product as well as of other assets
needed, such as cell lines and media of clinical grade, or
enabling tools for e.g. encapsulation or administration.
Finally, as the provider of the cell therapy, the pharmaceut-
ical company will sustain their business in the health care
system and build their capacity to meet the novel era which
is anticipated to radically change how diseases are treated
today. Together, the partners of the Triple Helix model will
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applications with a speed that would have been impos-
sible for any of the partners operating in isolation.
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